- BNTX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
-
Insider
- Institutional
- Shorts
-
CORRESP Filing
BioNTech SE (BNTX) CORRESPCorrespondence with SEC
Filed: 31 Mar 20, 12:00am
BioNTech SE
An der Goldgrube 12
D-55131 Mainz
Germany
March 31, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Paul Fischer
Re: | BioNTech SE | |
Registration Statement on Form F-4 Filed March 31, 2020 | ||
File No. 333-237515 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), BioNTech SE (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-4 (the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on April 2, 2020, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing.
Respectfully, | ||
BioNTech SE | ||
By: | /s/ Prof. Ugur Sahin, M.D. | |
Name: | Prof. Ugur Sahin, M.D. | |
Title: | Chief Executive Officer |
cc: | Brian K. Rosenzweig, Covington & Burling LLP |